BridgeBio Pharma Inc Net Assets
BridgeBio Pharma Inc net assets. Based on the latest financial reports, BridgeBio Pharma Inc (BBIO) has net assets worth $-2.51 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.22 Billion) and total liabilities ($3.72 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BridgeBio Pharma Inc (BBIO) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.51 Billion |
| % of Total Assets | -205.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 412.49 |
Net Assets of BridgeBio Pharma Inc (2017–2025)
Net assets of BridgeBio Pharma Inc from 2017 to 2025. This chart illustrates how BridgeBio Pharma Inc's net assets have evolved over time, based on quarterly financial data. See BBIO net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for BridgeBio Pharma Inc (2017–2025)
The table below shows the annual net assets of BridgeBio Pharma Inc from 2017 to 2025. For live market cap and overall valuation, see BBIO company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-2.08 Billion | -42.46% |
| 2024-12-31 | $-1.46 Billion | -8.57% |
| 2023-12-31 | $-1.34 Billion | -7.84% |
| 2022-12-31 | $-1.24 Billion | -43.83% |
| 2021-12-31 | $-865.58 Million | -902.31% |
| 2020-12-31 | $107.89 Million | -77.33% |
| 2019-12-31 | $475.98 Million | +568.93% |
| 2018-12-31 | $-101.50 Million | -85.61% |
| 2017-12-31 | $-54.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BridgeBio Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 375976700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
BridgeBio Pharma Inc Net Assets Breakdown (December 2025)
BridgeBio Pharma Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $202.00K | % |
| Other Comprehensive Income | $12.00K | % |
| Other Components | $1.74 Billion | % |
| Total Equity | $-2.08 Billion | 100.00% |
BridgeBio Pharma Inc Competitors by Market Cap
The table below lists competitors of BridgeBio Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yunnan Aluminium Co Ltd
SHE:000807
|
$12.73 Billion |
|
COLOPLAST SP.ADR 1/10 DK1
F:CBH
|
$12.73 Billion |
|
Lifco AB (publ)
ST:LIFCO-B
|
$12.74 Billion |
|
Shanghai Rural Commercial Bank Co Ltd
SHG:601825
|
$12.74 Billion |
|
GRAB HOLDINGS LTD CL.A
F:A6I
|
$12.71 Billion |
|
Taiwan Mobile Co Ltd
TW:3045
|
$12.70 Billion |
|
Guardant Health Inc
NASDAQ:GH
|
$12.69 Billion |
|
Wolters Kluwer N.V.
AS:WKL
|
$12.69 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BridgeBio Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,467,904,000 to -2,076,581,000, a change of -608,677,000.
- Net loss of 729,306,000 reduced equity.
- Share repurchases of 48,276,000 reduced equity.
- Other comprehensive income increased equity by 4,001.
- Other factors increased equity by 168,900,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-729.31 Million | -35.12% |
| Share Repurchases | $48.28 Million | -2.32% |
| Other Comprehensive Income | $4.00K | +0.0% |
| Other Changes | $168.90 Million | +8.13% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares BridgeBio Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.63 | $74.03 | x |
| 2018-12-31 | $-1.78 | $74.03 | x |
| 2019-12-31 | $3.89 | $74.03 | x |
| 2020-12-31 | $0.49 | $74.03 | x |
| 2021-12-31 | $-6.03 | $74.03 | x |
| 2022-12-31 | $-8.51 | $74.03 | x |
| 2023-12-31 | $-8.32 | $74.03 | x |
| 2024-12-31 | $-7.89 | $74.03 | x |
| 2025-12-31 | $-10.53 | $74.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BridgeBio Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -145.26%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-93.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.76 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-114.35 Million |
| 2019 | -63.76% | -642.10% | 0.06x | 1.55x | $-301.28 Million |
| 2020 | -774.92% | -5439.74% | 0.01x | 12.15x | $-454.51 Million |
| 2021 | 0.00% | -806.90% | 0.07x | 0.00x | $-475.50 Million |
| 2022 | 0.00% | -619.70% | 0.12x | 0.00x | $-355.72 Million |
| 2023 | 0.00% | -6913.92% | 0.02x | 0.00x | $-507.78 Million |
| 2024 | 0.00% | -241.44% | 0.24x | 0.00x | $-388.97 Million |
| 2025 | 0.00% | -145.26% | 0.54x | 0.00x | $-521.65 Million |
Industry Comparison
This section compares BridgeBio Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BridgeBio Pharma Inc (BBIO) | $-2.51 Billion | 0.00% | N/A | $12.71 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopteri… Read more